15
Participants
Start Date
August 30, 2022
Primary Completion Date
February 1, 2025
Study Completion Date
February 1, 2027
BEAM-101
Single dose of BEAM-101 administered by IV following myeloablative conditioning with busulfan
RECRUITING
Columbia University Irving Medical Center, New York
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Children's Hospital of Philadelphia, Philadelphia
RECRUITING
Medical University of South Carolina, Charleston
RECRUITING
Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center - Egleston Hospital, Atlanta
RECRUITING
Mayo Clinic Florida, Jacksonville
RECRUITING
University of Alabama at Birmingham, Birmingham
RECRUITING
The Children's Hospital at TriStar Centennial, Nashville
RECRUITING
St Jude Children's Research Hospital, Memphis
RECRUITING
University Hospitals Cleveland Medical Center, Cleveland
RECRUITING
The Cleveland Clinic Foundation, Cleveland
RECRUITING
Henry Ford Cancer Center, Detroit
RECRUITING
Medical College of Wisconsin, Milwaukee
RECRUITING
University of Minnesota, Minneapolis
RECRUITING
Washington University School of Medicine in St. Louis, St Louis
RECRUITING
Phoenix Children's Hospital, Phoenix
RECRUITING
Lucile Packard Children's Hospital at Standford, Palo Alto
RECRUITING
University of Miami, Miami
RECRUITING
Boston Children's Hospital, Boston
RECRUITING
Hackensack University Medical Center, Hackensack
Lead Sponsor
Beam Therapeutics Inc.
INDUSTRY